AT-60 A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM

BACKGROUND: This double-blinded randomized phase 2 trial of ICT-107 in newly-diagnosed glioblastoma (GBM) patients rigorously tested efficacy, safety, QoL, and immune response. METHODS: HLA-A1+ and/or -A2+ resected patients with residual tumor <1 cm(3) received 6wks of concurrent temozolomide (TM...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Neuro Oncol
मुख्य लेखकों: Wen, Patrick, Reardon, David, Phuphanich, Surasak, Aiken, Robert, Landolfi, Joseph, Curry, William, Zhu, Jay-Jiguang, Glantz, Michael, Peereboom, David, Markert, James, Larocca, Renato, O'Rourke, Donald, Fink, Karen, Kim, Lyndon, Gruber, Michael, Lesser, Glenn, Pan, Ed, Kesari, Santosh, Yu, John
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2014
विषय:
Adult Clinical Trials
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217840/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.59
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन